BACKGROUND: @entity1363 and @entity1875 are sedative agents commonly administered to @entity1 with @entity1545 . We compared plasma concentrations of glial cell @entity4483 protein and @entity842 (NO) between @entity1 who received @entity1363 and those who received @entity1875 sedation after severe @entity1545 , and investigated the association between @entity4483 and NO concentrations and neurological outcome. DESIGN: 28 @entity1 with severe @entity542 (Glasgow @entity772 Score <9) who required sedation and ventilation were randomly assigned to receive @entity1363 (n =15) or @entity1875 (n = 13) based sedation. Blood samples were drawn daily for 5 days for estimation of @entity4483 and NO concentrations. Neurological outcome was assessed 3 months later as good (Glasgow Outcome Score [GOS], 4-5) or poor (GOS, 1-3). RESULTS: A good neurological outcome was observed in 8/15 @entity1 (53%) in the @entity1363 group and 7/13 @entity1 (54%) in the @entity1875 group. @entity1 with a poor outcome had higher serum @entity4483 concentrations on ICU admission and on Days 1-4 in the ICU than those with a good outcome (mean [SD] on Day 1, 0.99 [0.81] v 0.41 [0.4] microg/L; Day 2, 0.80 [0.81] v 0.41 [0.24] microg/L; Day 3, 0.52 [0.55] v 0.24 [0.25] microg/L; and Day 4, 0.54 [0.43] v 0.24 [0.35] microg/L; P<0.05). There was no significant difference on Day 5. Plasma NO concentrations were not associated with outcome. In subgroup analysis, there was no difference in @entity4483 and NO concentrations between @entity1 with a good outcome versus those with a poor outcome in either the @entity1363 or @entity1875 group. CONCLUSIONS: Plasma concentrations of markers of @entity16 in @entity1 with severe @entity542 were similar in those who received @entity1363 sedation and those who received @entity1875 . @entity1 who had a poor neurological outcome at 3 months had consistently higher serum @entity4483 concentrations during the initial 4 days after injury than @entity1 who had a good outcome.

Effect of @entity1363 versus @entity1875 sedation on markers of XXXX and outcome after isolated severe @entity542 : a pilot study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1545 :: ('MESH:D020214', 'Disease') :: ['brain injury'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological injury'] @entity542 :: ('MESH:D006259', 'Disease') :: ['head injury'] @entity4483 :: ('6285', 'Gene') :: ['S100beta'] @entity772 :: ('MESH:D003128', 'Disease') :: ['Coma'] @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide'] @entity1875 :: ('MESH:D015742', 'Chemical') :: ['propofol'] @entity1363 :: ('MESH:D008874', 'Chemical') :: ['midazolam', 'Midazolam']
@entity16 :: (MESH:D009422,Disease) :: ['neurological injury']
